Skip to main content
Premium Trial:

Request an Annual Quote

Foundation Medicine Collaborating with Array BioPharma on Cancer Biomarkers

Premium

Foundation Medicine said this week that it is working with Array BioPharma to help identify cancer patients who will respond to targeted therapy with Array's cancer agents.

Under the collaboration, Foundation Medicine will use its DNA sequencing and analysis capabilities to determine the genetic profile of tumors from patients who are treated with Array's drugs.

Array BioPharma has a number of targeted cancer agents in early stages of clinical development. The goal of the partnership is to be able to identify patients who may respond to treatment with a specific drug.

Foundation Medicine already has a number of other partnerships with pharmaceutical companies, including Sanofi, Johnson & Johnson, Novartis, and Celgene.

The company plans to launch its targeted sequencing-based cancer diagnostic test to identify clinically actionable mutations in June (CSN 2/22/2012).

The Scan

Fertility Fraud Found

Consumer genetic testing has uncovered cases of fertility fraud that are leading to lawsuits, according to USA Today.

Ties Between Vigorous Exercise, ALS in Genetically At-Risk People

Regular strenuous exercise could contribute to motor neuron disease development among those already at genetic risk, Sky News reports.

Test Warning

The Guardian writes that the US regulators have warned against using a rapid COVID-19 test that is a key part of mass testing in the UK.

Science Papers Examine Feedback Mechanism Affecting Xist, Continuous Health Monitoring for Precision Medicine

In Science this week: analysis of cis confinement of the X-inactive specific transcript, and more.